Skip to main content
. 2022 May 12;17:91. doi: 10.1186/s13014-022-02063-w

Fig. 5.

Fig. 5

Analysis of the association between survival outcomes and pre-treatment serum SCC in T1/T2N0 subgroup. Pretreatment serum squamous cell carcinoma antigen (SCC Ag) correlated with a overall survival, b progression-free survival, c locoregional recurrence-free survival, d and distant metastasis-free survival in the T1/T2N0 subgroup